Impact of a Mediterranean diet on quality of life for multiple sclerosis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how following a Mediterranean diet may improve the quality of life for patients with multiple sclerosis (MS). It is a randomized controlled trial that aims to provide empirical evidence on the effects of dietary interventions, specifically the Mediterranean diet, on MS symptoms and overall well-being. The study will include patients with confirmed MS who have been on a stable medication regimen for at least six months. By comparing the quality of life outcomes between those adhering to the Mediterranean diet and a control group, the study seeks to clarify the potential benefits of this dietary approach for MS patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed MS based on 2017 Mcdonald criteria, with stable medication regimen in the previous six months.

Exclusion Criteria:

* Pregnancy or lactating
* People with a lack of judgment
* Serum creatinine ≥2 mg/dL(177 μmol per liter) or more
* Patients who had gastrointestinal problems that would prevent them from following any of the test diets
* Patients who had liver dysfunction (an increase by a factor of at least two above the upper limit of normal in alanine aminotransferase and aspartate aminotransferase levels)
* Active cancer or chemotherapy treatment in the last three years.

Where it's running

• Tel Aviv Sourasky medical center
  Tel Aviv, Israel, Israel Recruiting

Study contacts

• Principal investigator: Vered Kaufman-Shriqui, PhD — Ariel University
• Study coordinator: Arnon Karni, MD
• Email: arnonk@tlvmc.gov.il
• Phone: +972-52-426-6733

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treadmill-based virtual reality walking training for MS patients

  This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.

  Recruiting Shepherd Center, Atlanta GA · Atlanta, Georgia · NCT07927439

• Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS

  This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.

  Recruiting Cairo University · Giza, Giza Governorate · NCT07918339

• REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care

  This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.

  Recruiting Imperial College London · London and 2 other locations · NCT07899502

• Tolebrutinib in real-world MS care for patients treated by clinicians

  This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.

  Recruiting Sanofi · Marina, Abu Dhabi Emirate · NCT07898371

• Pilates via live video vs. prerecorded videos for people with multiple sclerosis

  This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.

  Recruiting Yuzuncu Yil University · Van · NCT07893925

• Cooling During Inpatient Rehab for People with MS

  This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.

  Recruiting Klinik Valens · Valens, Canton of St. Gallen · NCT07852156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.